Neo-MASCT

BIOLOGICAL2 trials

Sponsors

Sun Yat-sen University, The First People's Hospital of Lianyungang

Conditions

HepatectomyImmunotherapyNSCLC Stage IVPrimary Liver CancerRadiofrequency Ablation

Phase 1

Neo-MASCT Immunotherapy for Advanced NSCLC.

The First People's Hospital of LianyungangNSCLC Stage IV

Start: 2017-08-31End: 2019-11-30Target: 20Updated: 2017-07-05

Phase 2

RFA or Surgical Resection Combined With Neo-MASCT for Primary HCC: a Phase II Trial

Sun Yat-sen UniversityHepatectomy, Immunotherapy, Primary Liver Cancer +1

Start: 2017-07-25End: 2023-03-31Target: 98Updated: 2022-01-26

Related Papers

Efficacy and safety of PD-1 blockade-activated neoantigen specific cellular therapy for advanced relapsed non-small cell lung cancer.

2025-01-032 citations

Combination Neoantigen-Based Dendritic Cell Vaccination and Adoptive T-Cell Transfer Induces Antitumor Responses Against Recurrence of Hepatocellular Carcinoma

Cancer Immunology Research2022-04-2769 citations